References
- Purdon SE. Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophr Res 1999;35:s51–s60
- Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiat Res 1998;32:215–28
- Collaborative Working Group on Clinical Trial Evaluation. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. J Clin Psychiatry 1998;59:s3–s9
- Tandon R, Milner K, Jibson MD. Antipsychotics from theory to practice: integrating clinical and basic data. J Clin Psychiatry 1999;60:s21–s28
- Bobes J, González G, Portilla MP, et al. Calidad de vida en las esquizofrenias. Barcelona: J.R. Prous Editores; 1995
- Sartorius N. Fighting schizofrenia and its stigma. A new World Psychiatric Association educational programme. Br J Psychiatry 1997;170:297
- Priebe S, Oliver JPJ, Kaiser W, editors. Quality of life and mental health care. Petersfield: Wrightson Biomedical; 1999
- Rudnick A. Quality of life and atypical antipsychotics. J Clin Psychopharmacol 1999;18:424–5
- Tollefson GD, Andersen SW. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life. J Clin Psychiatry 1999;60:s23–s29
- Patrick DL, Erikson P. Health status and health policy: quality of life in health care evaluation and resource allocation. New York: Oxford University Press; 1993
- McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires, 2nd ed. New York: Oxford University Press; 1996
- Awad AG, Voruganti LN, Heslegrave RJ. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics 1997;11:32–47
- Kind, P. The EuroQoL Instrument: an index of HRQOL. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials, 2nd ed. Philadelphia: Lippincott-Raven; 1996. p. 191–201
- Brooks R, The EuroQol Group. EuroQol: the current state of play. Health Policy 1996;37:53–72
- Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan general population: feasibility and construct validity. Qual Life Res 1998;7:311–22
- Badia X, Roset M, Herdman, et al. The Spanish version of EuroQol: a description and its applications. Med Clin 1999;112:s79–s86
- Raisch DW. Understanding quality of life years and their application to pharmacoeconomic research. Ann Pharmacother 2000;34:906–14
- Gómez JC, Sacristán JA, Hernández J, et al. The safety of olanzapine compared to other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO study). J Clin Psychiatry 2000;61:335–43
- Sacristán JA, Gómez JC, Montejo AL, et al. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. Clin Ther 2000;22:583–99
- International statistical classification of diseases and related health problems, 10th Revision (ICD-10). Geneva: World Health Organization; 1994
- Bennet KJ, Torrance GW. Measuring health state preferences and utilities: rating scales, time trade-off, and standard gamble techniques. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials, 2nd ed. Philadelphia: Lippincott-Raven; 1996. p. 253–65
- Badia X, Herdman M, Schiaffino A. Determining correspondence between scores on the EQ-5D ‘thermometer’ and a 5-point categorical rating scale. Med Care 1999;37: 671–7
- Guy W. Clinical global impressions. In: Rockville GW, editor. ECDEU assessment manual for psychopharmacology [revised]. Rockville, MD: National Institute of Mental Health; 1976
- American Psychiatric Association diagnostic and statistical manual of mental disorders, 4th ed. (DSM-IV). Washington (DC): American Psychiatric Press; 1994
- Rabkin JG, Rabkin R, Wagner G. Testosterone replacement therapy in HIV illness. Gen Hosp Psychiatry 1995;17:37–42
- Ravizza L, Barzega G, Bellino S, et al. Predictors of drug response in obsessive–compulsive disorder. J Clin Psychiatry 1995;56:368–73
- Salzmann E, Robin JL. Multicentric double-blind study comparing efficacy and safety of minaprine and imipramine in dysthymic disorders. Pharmacopsychiatry 1995;31:68–75
- Spearing MK, Robert MP, Leverich GS, et al: Modification of the clinical global impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997;73:159–71
- Nunnally JC, Bernstein IH. Psychometric theory, 3rd ed. New York: McGraw-Hill; 1994
- Messick S. Validity of psychological assessment: validation of inferences from persons’ responses and performances as scientific inquiry into score meaning. American Psychologist 1995;50:741–9
- Cohen, J. Statistical power analysis for the behavioral sciences, 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associate Publishers; 1988
- Brazier J, Jones N, Kind P. Testing the validity of the EuroQol and comparing it with the SF36 health survey questionnaire. Qual Life Res 1993;2: 169–80
- McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res 1995;4:293–307
- Giner J, Ibañez E, Baca E, et al. Desarrollo del cuestionario Sevilla de Calidad de Vida (CSCV). Actas Luso-Españolas de Neurolgía, Psiquiatr Ciencias Afines 1997;25:11s–23s
- Ibañez E, Giner J, Cervera S, et al. El cuestionario Sevilla de Calidad de Vida: propiedades psicométricas. Actas Luso-Españolas de Neurolgía, Psiquiatr Ciencias Afines 1997;25:24s–31s
- Wilkinson GS, Hesdon B, Wild D, et al. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry 2000;177:42–6
- Gaite L, Vazquez-Barquero JL, Arrizabalaga A, et al. Quality of life in schizophrenia: development, reliability and internal consistency of the Lancashire Quality of Life Profile – European Version. EPSILON Study 8. European Psychiatric Services: inputs linked to outcome domains and needs. Br J Psychiatry 2000;39:s49–s54
- Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the evaluation of health care programme, 2nd ed. New York: Oxford University Press; 1997
- Nord E. Cost-value analysis in health care: making sense out of QALYs. Cambridge: Cambridge University Press; 1999